Why is "A1AT" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-17 23:13:31
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Alpha-1 antitrypsin or α1-antitrypsin is a protein belonging to the serpin superfamily. It is encoded in humans by the SERPINA1 gene. A protease inhibitor, it is also known as alpha1–proteinase inhibitor (A1PI) or alpha1-antiproteinase (A1AP) because it inhibits various proteases. As a type of enzyme inhibitor, it protects tissues from enzymes of inflammatory cells, especially neutrophil elastase.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Scaled up fed-batch production of recombinant alpha-1-antitrypsin by CHO cells in single-use surface aerated orbital shaken bioreactor - Nature
-
RBC Capital reiterates Beam Therapeutics stock rating on A1AT data - Investing.com
-
Wave Life Sciences (WVE) to Benefit From Optimism Surrounding Alpha-1 Antitrypsin Deficiency Program - Yahoo Finance
-
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency - BioSpace
-
Alpha-1 Antitrypsin Deficiency Market to Reach USD 9.64 - GlobeNewswire
-
The Viking Connection to Alpha-1 Antitrypsin Deficiency - Global Biotechnology Company
-
Case Report: Pseudomonas liver abscess in a previously healthy child with homozygous pathogenic S allele variant of the SERPINA1 gene - Frontiers
-
Delivering base editors to the liver and lungs in alpha-1 antitrypsin deficiency - Nature
-
Wave dips after GSK-partnered AATD therapy data update - FirstWord Pharma
-
Wave RNA editing restores enzyme in genetic condition but underwhelms investors - Fierce Biotech
-
Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency - NEJM
-
A Case of Acetaminophen Toxicity in a Patient With an Unusual Alpha-1 Antitrypsin Phenotype - Cureus
-
YolTech Therapeutics gains FDA approval for Phase II/III AATD trial - Clinical Trials Arena
-
Alpha 1 Antitrypsin Deficiency Augmentation Therapy Market Size to Hit USD 2.96 Bn by 2034 - Precedence Research
-
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency - Intellia Therapeutics
-
COVID-19 outcomes in individuals with severe alpha-1 antitrypsin deficiency in Sweden - Nature
-
Oxidation-dependent effects of alpha-1 antitrypsin on wound healing and inflammation | Scientific Reports - Nature
-
Altered polyadenylation site usage in SERPINA1 3’UTR in response to cellular stress affects A1AT protein expression - Nature
-
Selection for somatic escape variants in SERPINA1 in the liver of patients with alpha-1 antitrypsin deficiency - Nature
-
A1AT dysregulation of metabolically stressed hepatocytes by Kupffer cells drives MASH and fibrosis - Nature
-
Wave Crashes Despite Successful RNA Editing in AATD Study - BioSpace
-
Association of A1AT With Poor Functional Outcome in Patients With Acute Ischemic Stroke - American Heart Association Journals
-
Role of alpha-1 antitrypsin in Bruch’s membrane integrity - Nature
-
Case Report: A Triple-organ Transplant for Comorbidities of Alpha-1 Antitrypsin Deficiency - Cleveland Clinic
-
Alpha1-Antitrypsin Deficiency - NEJM
-
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead - Arrowhead Pharmaceuticals, Inc.
-
Tessera Therapeutics: addressing Alpha-1 Antitrypsin Deficiency - Drug Target Review
-
Alpha-1: A story of underdiagnosed genetic liver disease - Takeda Pharmaceuticals
-
Alpha-1 antitrypsin inhibits Clostridium botulinum C2 toxin, Corynebacterium diphtheriae diphtheria toxin and B. anthracis fusion toxin | Scientific Reports - Nature
-
Beam Therapeutics Reports Clinical Proof-Of-Concept Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Trial - CRISPR Medicine News
-
Maternal serum alpha-1 antitrypsin levels in spontaneous preterm and term pregnancies - Nature
-
Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency - Nature
-
Multiplex quantification of C-terminal alpha-1-antitrypsin peptides provides a novel approach for characterizing systemic inflammation - Nature
-
Pulmonary transplantation of alpha-1 antitrypsin (AAT)-transgenic macrophages provides a source of functional human AAT in vivo - Nature
-
Regeneron, Tessera to advance gene editing therapy for AATD: Deals Report - BioCentury
-
Alpha-1 Antitrypsin Deficiency: Answers to 5 Frequently Asked Questions - American Lung Association
-
Leave no one behind: inclusion of alpha-1 antitrypsin deficiency patients in COVID-19 vaccine trials - Nature
-
The Role of Gene Therapy as an Emerging Treatment Strategy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease: A Systematic Review - Cureus
-
Identification of an alpha-1 antitrypsin variant with enhanced specificity for factor XIa by phage display, bacterial expression, and combinatorial mutagenesis - Nature
-
Wave Life Sciences Achieves RNA Editing in Trial for WVE-006 in Alpha-1 Antitrypsin Deficiency - CGTLive®
-
Alpha-1 Antitrypsin Deficiency Market Size to Reach USD 4.4 Million by 2035, Impelled by Increasing Awareness and Diagnosis Rates - BioSpace
-
Alpha-1 Antitrypsin Deficiency: Home Therapy - Frontiers
-
A combined in silico and in vitro study on mouse Serpina1a antitrypsin-deficiency mutants - Nature
-
Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency - Intellia Therapeutics
-
John Magenau, MD, on Alpha-1-Antitrypsin for High-Risk Acute GVHD - The ASCO Post
-
A stacking ensemble machine learning model to predict alpha-1 antitrypsin deficiency-associated liver disease clinical outcomes based on UK Biobank data - Nature
-
Beam gene therapy for protein deficiency passes early safety test, sets efficacy bar in space: analyst - Fierce Biotech
-
Opinion: New Therapies Are Set to Upend Treatment of Genetic Disorder AATD - BioSpace
-
Alpha-1 Antitrypsin Deficiency Market to Register Incremental Growth by 2032, Assesses DelveInsight | Key Companies - Kamada Pharmaceuticals, Arrowhead Pharmaceuticals, Takeda, Mereo BioPharma, AstraZeneca, Inhibrx, Novo Nordisk - PR Newswire
-
Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection - Nature
-
Korro Bio to Begin RNA-Editing Trial in Alpha-1 Antitrypsin Deficiency - CRISPR Medicine News
-
Intellia Obtains UK Clearance to Begin Gene Insertion Trial in Alpha-1 Antitrypsin Deficiency - CRISPR Medicine News
-
Company to Deploy Gene Editing for Alpha-1 Disease | RT - respiratory-therapy.com
-
IgE-tailpiece associates with α-1-antitrypsin (A1AT) to protect IgE from proteolysis without compromising its ability to interact with FcεRI | Scientific Reports - Nature
-
FDA Approves Test for the Genetic Diagnosis of Alpha-1 Antitrypsin Deficiency - Clinical Lab Products
-
Alpha-1 antitrypsin augmentation therapy decreases miR-199a-5p, miR-598 and miR-320a expression in monocytes via inhibition of NFκB - Nature
-
'Rescue' mutations can protect liver from damage in patients with genetic disorder - Medical Xpress
-
Purified A1AT holds promise as therapy for acute liver failure - Nature
-
INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing - PR Newswire
-
Phospholipid transfer protein and alpha-1 antitrypsin regulate Hck kinase activity during neutrophil degranulation - Nature
-
Lung function improves with endobronchial valve in COPD, alpha-1 antitrypsin deficiency - Healio
-
Neurodevelopmental Deficits in Children With Inherited Cholestatic Liver Disorders - Gastroenterology Advisor
-
Editor’s Pick: Overview of Alpha-1 Antitrypsin Deficiency-Mediated Liver Disease - European Medical Journal
-
Orphan drug development in alpha-1 antitypsin deficiency - Nature
-
Somatic Escape Mutations Offer New Insights Into Chronic Liver Disease - Inside Precision Medicine
-
Vertex Scraps Two Phase I AATD Candidates Following Disappointing Data - BioSpace
-
The structural basis for Z α1-antitrypsin polymerization in the liver - Science | AAAS
-
Alpha1-Antitrypsin Deficiency — A Model for Conformational Diseases - NEJM
-
Vertex, beaten by rare disease again, drops 2 assets on growing discard pile - Fierce Biotech
-
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size - Market.us
-
A mutant α1antitrypsin in complex with heat shock proteins as the primary antigen in type 1 diabetes in silico investigation - Nature
-
News - Viking Adaptation Predisposes Descendants to Disease - Archaeology Magazine
-
Investigating the relationship between COPD and liver disease in alpha-1 antitrypsin deficiency - News-Medical
-
Alpha 1 Antitrypsin Deficiency (AATD) Treatment Market Size, 2034 - Fortune Business Insights
-
Hepatic steatosis depresses alpha-1-antitrypsin levels in human and rat acute pancreatitis - Nature
-
Practical genetics: alpha-1-antitrypsin deficiency and the serpinopathies - Nature
-
Aggregation of M3 (E376D) variant of alpha1- antitrypsin - Nature
-
Three missense variants of metabolic syndrome-related genes are associated with alpha-1 antitrypsin levels - Nature
-
Site-Specific Conjugation of a Selenopolypeptide to Alpha-1-antitrypsin Enhances Oxidation Resistance and Pharmacological Properties - Wiley Online Library
-
Vikings, Worms, and Emphysema - Archaeology Magazine
-
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth 2032 - Fortune Business Insights
-
Exome Sequencing Reveals Immune Genes as Susceptibility Modifiers in Individuals with α - Nature
-
What I Mean When I Say 'I'm Purely a Lung Girl' - The Mighty. Making health about people.
-
Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer - Nature
-
Potential Use of Alpha-1 Anti-trypsin in the Covid-19 Treatment - Frontiers
-
Vikings’ Parasites May Have Led to Lung Problems in Their Modern Descendants - Mental Floss
-
A new therapeutic strategy is being investigated to treat alpha-1 antitrypsin deficiency (AATD), a rare hereditary disease - uv.es
-
AIRNA Closes $155M Series B Round to Fund ATTD Trial, Build Pipeline - Genetic Engineering and Biotechnology News
-
CEBPB-mediated upregulation of SERPINA1 promotes colorectal cancer progression by enhancing STAT3 signaling - Nature
-
Viking gene may carry predisposition to lung disease - ZME Science
-
Dual gene therapy approach may treat AAT lung, liver disease - UMass Chan Medical School
-
Intellia trims more than a quarter of its staff, culls early-stage lung disease asset - FirstWord Pharma
-
Takeda, Arrowhead hit one target for rare disease drug, but placebo overperformance sends biotech's shares tumbling - Fierce Biotech
-
Korro secures approvals in Australia to commence AATD trial of KRRO-110 - Clinical Trials Arena
-
First treatment for liver damage in alpha-1-antitrypsin deficiency - MedUni Wien
-
Roadworks on A1 at Peterborough to last until December 2027 after fatal crash in 2024 - Peterborough Telegraph
-
High-resolution ex vivo NMR spectroscopy of human Z α - Nature
-
Fetal bovine serum albumin inhibits antimicrobial peptide activity and binds drug only in complex with α1-antitrypsin - Nature
-
The Vikings, their worms, and the diseases they got - Medievalists.net
-
Alpha1-Antitrypsin Deficiency - NEJM
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.